News Bukwang Pharmaceutical Co., Ltd.

Equities

A003000

KR7003000007

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-09 pm EDT			5-day change	1st Jan Change
6,600 ^KRW	-1.79%		+3.45%	+8.20%

Apr. 01	H Delta Private Equity Partnership completed the acquisition of 24.4% stake in Contera Pharma ApS from Bukwang Pharmaceutical Co., Ltd. for KRW 6.3 billion.	CI
Mar. 26	Bukwang Pharmaceutical Shares Surge Following Buyback Program Announcement	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

H Delta Private Equity Partnership completed the acquisition of 24.4% stake in Contera Pharma ApS from Bukwang Pharmaceutical Co., Ltd. for KRW 6.3 billion.	Mar. 31	CI
Bukwang Pharmaceutical Shares Surge Following Buyback Program Announcement	Mar. 26	MT
H Delta Private Equity Partnership agreed to acquire 24.4% stake in Contera Pharma ApS from Bukwang Pharmaceutical Co., Ltd. for KRW 6.3 billion.	Mar. 21	CI
Bukwang Pharmaceutical : IR Fact Book 4Q23 (Reviewed by External Auditor)	Mar. 14	PU
Bukwang Pharmaceutical : IR presentation 4Q23 (Reviewed by External Auditor)	Mar. 14	PU
Bukwang Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Bukwang Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Bukwang Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Bukwang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Bukwang Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-11	CI
Bukwang Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
Bukwang Pharmaceutical Co., Ltd.(KOSE:A003000) dropped from KOSPI 200 Index	22-06-09	CI
Bukwang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-13	CI
Bukwang Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-17	CI
OCI Company Ltd. completed the acquisition of additional 10.878134% stake in Bukwang Pharmaceutical Co., Ltd. (KOSE : A003000) from Kim Sanghun and 8 other shareholders for approximately KRW 150 billion.	22-03-02	CI
OCI Company Ltd. agreed to acquire an additional 10.878134% stake in Bukwang Pharmaceutical Co., Ltd. (KOSE : A003000) from Kim Sanghun and 8 other shareholders for approximately KRW 150 billion.	22-02-21	CI
ImmPACT Bio USA Inc. announced that it has received $110.855843 million in funding from a group of investors	22-01-19	CI
ImmPACT Bio USA Inc. announced that it expects to receive $110.855843 million in funding	22-01-13	CI
Bukwang Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-12	CI
Bukwang Pharmaceutical : confirmed Levovir showed tendency of reducing virus from Phase 2 clinical trial topline data	21-05-13	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Bukwang Pharmaceutical Co., Ltd.

Equities

A003000

KR7003000007

Summary

Filters